Drug intelligence / Profile preview

BCD-236

Development stage: Phase 2
Lead developer: Biocad

Overview

BCD-236 is an experimental drug currently being investigated for the treatment of relapsed and/or metastatic triple negative breast cancer. It is studied as a combination therapy with standard chemotherapeutic agents, and trials are assessing its efficacy, safety, pharmacokinetics, and immunogenicity[1][7][10]. Specific details about its molecular structure, precise mechanism of action, and pharmacological class are not publicly disclosed in available clinical trial registries as of August 2025[1][7][10].

Brand names: BCD-236BCD236BCD 236
Other names: BCD-236BCD236BCD 236

Beyond the preview

Go deeper on BCD-236.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-236.

Explore the full profile